Search clinical trials for: Nemiralisib

Total 13 results

GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation

Pulmonary Disease, Chronic Obstructive

Canada, Denmark
GlaxoSmithKline

Completed

An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Romania, Russian Federation, Belgium, Denmark, Netherlands
GlaxoSmithKline

Terminated

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Australia, Argentina, France, Germany, Poland, Romania, Russian Federation, Spain, United States, Netherlands, Sweden, Korea, Republic of, Canada, United Kingdom, Italy, Mexico
GlaxoSmithKline

Completed

Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI

Activated PI3K-delta Syndrome

United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

Absorption & Elimination of Radiolabelled GSK2269557

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557

Asthma

United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects

Pulmonary Disease, Chronic Obstructive

Japan

3

Subscribe